Evaluation of Novel Agents and Combinations Aims to Improve Outcomes in Frontline RCC

Ulka Nitin Vaishampayan, MBBS, discusses factors to consider for choosing between immuno-oncology/immuno-oncology and VEGF TKI/immuno-oncology combinations for the frontline treatment of patients with renal cell carcinoma, areas of ongoing research in this disease, and treatment updates across the prostate cancer spectrum.

Related Keywords

Ann Arbor ,Michigan ,United States ,Clara Hwang ,Ulka Nitin Vaishampayan ,Shawna Kraft ,Sarah Yentz ,Phasei Program ,University Of Michigan Rogel Cancer Center ,Rogel Cancer Center ,University Of Michigan ,Henry Ford Health ,Science Summit ,Michigan Rogel Cancer Center ,Patients With Metastatic Renal Cell Carcinoma ,Bbs ,The University Of Michigan ,Treatment Updates Across Prostate Cancer ,D ,Phd ,